Biomotion Sciences. Ordinary Shares SLXN 深 滬
等待開盤 12-24 09:30:00 美东时间
2.42
-0.070
-2.81%
華盛通- 最 高2.50
- 今 開2.50
- 成交量 1.10万股
- 最 低 2.4016
- 昨 收 2.49
- 總市值 2103.56万
- 52周最高 51.75
- 市盈率 靜 --
- 換手率 0.13%
- 52周最低 2.13
- 委 比 0.00%
- 總股本 869.24万
- 歷史最高 627.75
- 量 比 0.23
- 振 幅 3.95%
- 歷史最低 2.4016
- 每 手 1
- 風險率 8.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
12-16 09:36
Litchfield Hills Initiates Coverage On Silexion Therapeutics with Buy Rating, Announces Price Target of $6
Litchfield Hills analyst Theodore O'Neill initiates coverage on Silexion Therapeutics (NASDAQ:SLXN) with a Buy rating and announces Price Target of $6.
12-15 22:45
Silexion Therapeutics Receives Written Scientific Advice From German Regulator Regarding Proposed Design Of Phase 2/3 Clinical Study For SIL204 For Locally Advanced Pancreatic Cancer
Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it has received
12-02 21:04
Silexion Therapeutics Q3 EPS $(2.88) Beats $(3.40) Estimate
Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(2.88) per share which beat the analyst consensus estimate of $(3.40) by 15.29 percent. This is a 98.95 percent increase over losses of $(274.05) per
11-12 22:04
Silexion Therapeutics Unveils Promising SIL204 Data
An announcement from Silexion Therapeutics ( ($SLXN) ) is now available. On Sep...
09-30 21:24
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
Silexion Therapeutics Corp.'s SIL204 has shown high activity against multiple KRAS mutations across various cancer types, achieving inhibition rates of 83.5%-99.7%. It demonstrates first evidence in gastric cancer and expanded validation in colorectal cancer, targeting mutations like G12R (17% of pancreatic cancers) hard to inhibit. SIL204's broad mutation coverage and strong activity raise hopes for a comprehensive pan-KRAS therapeutic solution....
09-30 12:40
Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements
Silexion Therapeutics has regained compliance with Nasdaq's minimum bid price ($1.00 per share) and shareholders' equity ($2.5 million) requirements, ensuring continued listing on the Nasdaq Capital Market. The company highlights its strong financial foundation and upcoming Phase 2/3 clinical trials for SIL204, with preclinical data showing promising results for KRAS-driven cancers. Silexion remains committed to advancing RNAi therapies for under...
09-25 12:45
Why Is Silexion Therapeutics Stock (SLXN) Up 190% Today?
Silexion Therapeutics stock was up on Thursday after the company posted positiv...
09-11 20:15
Market-Moving News for September 11th
SLXN: 50% | Silexion Highlights Preclinical Data Of SIL204 Supporting Dual-Route Treatment Strategy With Phase 2/3 Trial On Track For 2026 VNCE: 242% | Vince Holding Q2 Adj. EPS $0.38 Beats $(0.10)
09-11 19:26
